Literature DB >> 2331442

Enhancement of the radiosensitivity of two human tumour cell lines by hexamethylene bisacetamide.

C A Bill1, C M Vines, K C Garrett, K Yamada, P J Tofilon.   

Abstract

The effect of the maturation-inducing polar solvent, hexamethylene bisacetamide (HMBA), on the radiosensitivity of two human tumour cell lines (clone A, a colon carcinoma; and EJ, a bladder carcinoma) was investigated. Exposure of clone A or EJ cells to HMBA resulted in a concentration-dependent increase in doubling time, a decreased plating efficiency and changes in cell morphology, which are consistent with the formation of a better-differentiated phenotype. Growth of clone A cells in 2 or 3 mM HMBA, followed by irradiation and plating into HMBA-free medium, resulted in a significant enhancement in radiosensitivity, as determined by colony-forming ability. A similar increase in radiosensitivity was detected for EJ cells; however, for these cells a concentration of 7 mM HMBA was required. The increased radiosensitivity caused by HMBA was observed primarily in the low-dose, shoulder region of the gamma-ray cell survival curves for both cell lines, which is reflected by an increase in the alpha component of the survival curve with essentially no effect on beta. These data indicate that HMBA can radiosensitise human tumour cells at concentrations and for exposure periods that can be achieved in the clinic.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2331442      PMCID: PMC1971349          DOI: 10.1038/bjc.1990.126

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  24 in total

1.  Enhanced X ray sensitivity of human colon tumor cells by combination of N-methylformamide with chemotherapeutic agents.

Authors:  J T Leith; E S Lee; D V Leite; A S Glicksman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-08       Impact factor: 7.038

2.  Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals.

Authors:  C W Young; M P Fanucchi; T Declan Walsh; L Baltzer; S Yaldaei; Y W Stevens; C Gordon; W Tong; R A Rifkind; P A Marks
Journal:  Cancer Res       Date:  1988-12-15       Impact factor: 12.701

3.  Enhancement of radiation injury in human colon tumor cells by the maturational agent sodium butyrate (NaB).

Authors:  C M Arundel; A S Glicksman; J T Leith
Journal:  Radiat Res       Date:  1985-12       Impact factor: 2.841

4.  Initial slope of radiation survival curves is characteristic of the origin of primary and established cultures of human tumor cells and fibroblasts.

Authors:  E P Malaise; B Fertil; P J Deschavanne; N Chavaudra; W A Brock
Journal:  Radiat Res       Date:  1987-08       Impact factor: 2.841

5.  Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.

Authors:  M J Egorin; L M Sigman; D A Van Echo; A Forrest; M Y Whitacre; J Aisner
Journal:  Cancer Res       Date:  1987-01-15       Impact factor: 12.701

6.  Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580).

Authors:  B A Conley; A Forrest; M J Egorin; E G Zuhowski; V Sinibaldi; D A Van Echo
Journal:  Cancer Res       Date:  1989-06-15       Impact factor: 12.701

Review 7.  Cell kinetics and radiation biology.

Authors:  J Denekamp
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1986-02

8.  Chromatin modifications associated with N-methylformamide-induced radiosensitization of clone A cells.

Authors:  C M Arundel; C M Vines; P J Tofilon
Journal:  Cancer Res       Date:  1988-10-15       Impact factor: 12.701

9.  Modification of tumor and normal tissue radioresponse in mice by N-methylformamide.

Authors:  M Iwakawa; L Milas; N Hunter; P J Tofilon
Journal:  Int J Radiat Oncol Biol Phys       Date:  1987-01       Impact factor: 7.038

10.  Radiosensitization of primary human tumor cell cultures by N-methylformamide.

Authors:  C Arundel; S Bock; W A Brock; P J Tofilon
Journal:  Int J Radiat Oncol Biol Phys       Date:  1987-05       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.